Virax Biolabs Group Limited (VRAX)
| Market Cap | 1.59M -41.6% |
| Revenue (ttm) | 12,423 +96.2% |
| Net Income | -5.02M |
| EPS | -12.64 |
| Shares Out | 796.99K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 29,135 |
| Open | 2.130 |
| Previous Close | 2.110 |
| Day's Range | 1.980 - 2.130 |
| 52-Week Range | 1.830 - 21.750 |
| Beta | 1.39 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 20, 2026 |
About VRAX
Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease. It also provides ImmuneSelect, a research-use-only p... [Read more]
Financial Performance
In fiscal year 2026, Virax Biolabs Group's revenue was $12,423, an increase of 96.22% compared to the previous year's $6,331. Losses were -$5.02 million, -17.12% less than in 2025.
Financial StatementsNews
Virax Biolabs files to sell 1.68M ordinary shares for holders
16:21 EDT Virax Biolabs (VRAX) files to sell 1.68M ordinary shares for holders
Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement
Fiscal 2026 Annual Report, filed July 2, 2026, reflects cash of $6.4 million, total assets of $8.3 million and shareholders' equity attributable to ordinary shareholders of $7.3 million Fosun Diagnost...
Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
LONDON, July 10, 2026 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX) today closed its previously announced exercise of certain outstanding preferred investment o...
Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
LONDON, July 9, 2026 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX) announced today that it has entered into a definitive agreement for the immediate exercise of...
Why this biotech stock more than tripled on Thursday
Virax Biolabs (VRAX) shares exploded higher on Thursday morning after management announced a lucrative cross-border commercial breakthrough. In a press release dated July 9th, the company said its UK ...
Why Is Penny Stock Virax Biolabs (VRAX) Up Today?
Virax Biolabs stock saw massive gains on Thursday alongside a new deal with Fosun Diagnostics.
Virax Biolabs signs multi-country commercial agreement with Fosun Diagnostics
Virax Biolabs (VRAX) Group announced that its wholly owned subsidiary, Virax Biolabs Limited, has entered into an exclusive multi-country commercial supply agreement with Fosun Diagnostics for the Com...
Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics
LONDON, July 9, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that its wholly owned subsidiary, Virax Biolabs (UK) Limited, has entered int...
Virax Biolabs Group Ltd trading halted, news pending
19:50 EDT Virax Biolabs (VRAX) Group Ltd trading halted, news pending
Virax Biolabs approves share consolidation program
Virax Biolabs (VRAX) Group announced that the board of directors of the Company approved a share consolidation of the Company’s authorized, issued and outstanding ordinary shares of $0.001 par value…
Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation
LONDON, June 24, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that the board of directors of the Company approved a share consolidation of...
Virax Biolabs reports pilot data for ViraxImmune in Long COVID
Virax Biolabs (VRAX) Group reported positive early pilot performance data for ViraxImmune its blood-based test in development for Long COVID, myalgic encephalomyelitis/chronic fatigue syndrome, or ME/...
Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes
LONDON, May 26, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today reported positive early pilot performance data for ViraxImmune™, its blood-based test i...
Virax Biolabs CEO outlines strategic priorities, near-term milestones
Virax Biolabs (VRAX) published a shareholder letter from CEO James Foster and released an updated investor presentation. Together, these materials outline Virax’s current strategic and commercial fram...
Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to Shareholders
Virax Biolabs is advancing a focused strategy centered on ViraxImmune™ and a U.S. market-entry pathway, which management believes is not reflected in the Company's current public valuation despite its...
Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation
LONDON, March 31, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that Virax Biolabs (UK) Limited, its wholly owned subsidiary, has achieved ...
Virax Biolabs price target lowered to $1 from $3 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Virax Biolabs (VRAX) to $1 from $3 and keeps a Buy rating on the shares. Virax Biolabs outlined 2026 priorities focused on…
Virax Biolabs files to sell 25.875M ordinary shares for holders
16:13 EST Virax Biolabs (VRAX) files to sell 25.875M ordinary shares for holders
Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement
Extends cash runway into first half of 2028, beyond planned completion of ViraxImmune™ US based regulatory study in post-acute sequelae of COVID-19 ("PASC", or long COVID) and submission to the FDA, c...
Virax Biolabs Group Limited Announces $5 Million Private Placement
LONDON , Dec. 3, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company dedicated to the advancement of immunology research and...
Why Is Virax Biolabs (VRAX) Stock Rocketing Higher Today?
Virax Biolabs stock rallied alongside a letter to shareholders concerning the company’s 2026 plans.
Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders
Virax Biolabs' proprietary in-development diagnostic technology for post-acute infection syndromes ("PAIS"), such as Long COVID, positions the Company for an important data year ahead, following a ser...
Virax completes patient recruitment for its clinical study evaluating ViraxImmun
Virax Biolabs (VRAX) Group announced that it has successfully completed patient recruitment for its United Kingdom-based, multi-centre clinical study evaluating the performance of the ViraxImmune assa...
Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes
LONDON , Nov. 3, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses to and dia...
Virax Biolabs partners with Emory University on ViraxImmune clinical studies
Virax Biolabs (VRAX) has signed a Research Services Agreement with Emory University’s Center for the Advancement of Diagnostics for a Just Society to conduct clinical studies of ViraxImmune. These stu...